AIHTA - Publications - Search - Elacestrant (Orserdu®) monotherapy for the treatment of oestrogen receptor (ER)‑positive, HER2-negative, locally advanced or metastatic breast cancer

Rothschedl, E. and Wolf, S. (2023): Elacestrant (Orserdu®) monotherapy for the treatment of oestrogen receptor (ER)‑positive, HER2-negative, locally advanced or metastatic breast cancer. Fact Sheet Nr. 140.

[thumbnail of Fact Sheet Nr.140.pdf]
Preview
 PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
113kB

Item Type:Horizon Scanning of Medicines
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WP Gynaecology > WP 800-910 Breast
Language:English
Series Name:Fact Sheet Nr. 140
Deposited on:21 Aug 2023 14:15
Last Modified:21 Aug 2023 14:24

Repository Staff Only: item control page